Literature DB >> 11242427

Early statin treatment following acute myocardial infarction and 1-year survival.

U Stenestrand1, L Wallentin.   

Abstract

CONTEXT: Randomized trials have established statin treatment as secondary prevention in coronary artery disease, but it is unclear whether early treatment with statins following acute myocardial infarction (AMI) influences survival.
OBJECTIVE: To evaluate the association between statin treatment initiated before or at the time of hospital discharge and 1-year mortality after AMI. DESIGN AND
SETTING: Prospective cohort study using data from the Swedish Register of Cardiac Intensive Care on patients admitted to the coronary care units of 58 Swedish hospitals in 1995-1998. One-year mortality data were obtained from the Swedish National Cause of Death Register. PATIENTS: Patients with first registry-recorded AMI who were younger than 80 years and who were discharged alive from the hospital, including 5528 who received statins at or before discharge and 14 071 who did not. MAIN OUTCOME MEASURE: Relative risk of 1-year mortality according to statin treatment.
RESULTS: At 1 year, unadjusted mortality was 9.3% (1307 deaths) in the no-statin group and 4.0% (219 deaths) in the statin treatment group. In regression analysis adjusting for confounding factors and propensity score for statin use, early statin treatment was associated with a reduction in 1-year mortality (relative risk, 0.75; 95% confidence interval, 0.63-0.89; P =.001) in hospital survivors of AMI. This reduction in mortality was similar among all subgroups based on age, sex, baseline characteristics, previous disease manifestations, and medications.
CONCLUSIONS: Early initiation of statin treatment in patients with AMI is associated with reduced 1-year mortality. These results emphasize the importance of implementing the results of randomized statin trials in unselected AMI patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11242427     DOI: 10.1001/jama.285.4.430

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  88 in total

1.  Use of Statins for Secondary Prevention.

Authors:  Antonios M. Xydakis; Peter H. Jones
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-02

2.  Suppression of Gαs synthesis by simvastatin treatment of vascular endothelial cells.

Authors:  Ruqin Kou; Takashi Shiroto; Juliano L Sartoretto; Thomas Michel
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

3.  Clinical implications of statin event trials.

Authors:  Anne Carol Goldberg
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

4.  Patients with acute coronary syndrome should start a statin while still in hospital.

Authors:  C G Isles
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

Review 5.  Comparing HMG-CoA reductase inhibitors.

Authors:  Peter H Jones
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 6.  Early use of statins in acute coronary syndromes.

Authors:  Joshua M Spin; Randall H Vagelos
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 7.  In-hospital initiation of statin therapy in patients with acute coronary events.

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 8.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.

Authors:  Goodarz Danaei; Mohammad Tavakkoli; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2012-01-05       Impact factor: 4.897

9.  Observer variability and optimal criteria of transient ischemia during ST monitoring with continuous 12-lead ECG.

Authors:  Tomas Jernberg; Jörgen Cronblad; Bertil Lindahl; Lars Wallentin
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

10.  The new definition of myocardial infarction--can we use it?

Authors:  Stefan Agewall; Christian Löwbeer
Journal:  Clin Cardiol       Date:  2005-02       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.